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Abstract
Objective. Real-world evidence of the long-term effectiveness of TNF-a inhibitor (TNFi) therapy in
patients with PsA is limited. This study was conducted to describe patterns of TNFi therapy and treat-
ment responses in patients with PsA treated in UK clinical practice.
Methods. A multicentre, retrospective, observational cohort study of consenting patients treated with
TNFi for PsA with 3 years follow-up from first TNFi initiation (observation period) was carried out in
11 UK National Health Service hospitals. Data were collected concerning baseline patient characteris-
tics, PsA-related treatment pathways and TNFi treatment responses (PsA response criteria compo-
nents: swollen/tender joint counts, physician and patient global assessments).
Results. The mean age of patients (n¼ 141) was 50.3 (S.D.: 12.1) years (50% male). During a median
observation period of 4.5 (range: 3.4–5.5) years, patients received a median of one (range: one to five)
TNFi. Twelve-week response rates for first TNFi (where available) were as follows: 80% (n¼ 64/80) for
swollen joint counts, 79% (n¼ 63/79) for tender joint counts, 79% (n¼ 37/47) for physician global
assessments, 69% (n¼ 41/59) for patient global assessments and 79% (n¼ 37/47) for PsA response
criteria. At the end of the observation period, the proportions of patients remaining on first, second,
third and fourth/fifth TNFi were 56, 15, 5 and 3%, respectively; 21% of patients permanently discontin-
ued TNFi therapy.
Conclusion. Long-term TNFi therapy is generally well tolerated and may be effective; however, after
initial TNFi failure, there appears to be progressively less benefit and more adverse effects with suc-
cessive TNFi switches. Strategies are needed for effective therapy for PsA beyond the first TNFi
failure.
Key words: psoriatic arthritis, tumour necrosis factor inhibitors, observational study, swollen joints, tender
joints, physician global assessment, patient global assessment, treatment persistence
Introduction
PsA is a progressive, chiefly autoinflammatory disease
with variable clinical manifestations, including peripheral
and axial joint inflammation, dactylitis, enthesitis, psoria-
sis and nail involvement [1]. The population prevalence
of PsA has been estimated at between 0.05 and 0.25%
in Europe and the USA [2]; PsA develops in up to 30%
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of patients with psoriasis, but the true prevalence of
PsA-sine-psoriasis is unknown [3, 4]. A variety of treat-
ment options are available for PsA, including NSAIDs,
glucocorticoid injections and DMARDs, including con-
ventional synthetic DMARDS (csDMARDs) and a rapidly
changing landscape of targeted biologic DMARD and
synthetic DMARD therapies [5–7]. TNF-a inhibitor (TNFi)
therapy is an important treatment option for patients
with PsA who are unresponsive to csDMARDs such as
MTX. Randomized controlled trials have shown that
TNFi therapies are more effective than placebo using a
variety of assessment criteria [8–12], slowing disease
progression and improving quality of life [5].
In the UK, the National Institute for Health and Care
Excellence (NICE) recommends TNFi therapy for
patients with active and progressive PsA who have pe-
ripheral arthritis with three or more tender joints and
three or more swollen joints and have not responded to
at least two csDMARDs, administered individually or in
combination [3, 13]. NICE guidance recommends that
TNFi therapy is discontinued in patients not achieving
an adequate response using the PsA response criteria
(PsARC) at 12 weeks, unless a psoriasis area and sever-
ity index 75 response has been achieved at 12 weeks
[3, 13]. There is evidence from a number of national reg-
istries showing that many patients remain on the first
TNFi over prolonged periods of time [14–20], although
whether this reflects treatment effectiveness or the his-
torical lack of alternative targeted therapies is unclear.
Additional real-world evidence is required to understand
the long-term effectiveness of TNFi therapy in routine
clinical practice, particularly in patients who have been
treated with multiple TNFi. A greater understanding of
the longer-term outcomes of patients with PsA treated
with TNFi will be useful for informing clinicians’ and
patients’ decisions about treatment options after failure
of TNFi, particularly given the recent availability of newer
therapies targeted towards non-TNF inflammatory path-
ways [1, 21]. The aim of this study was to describe the
patterns of first and subsequent TNFi use and response
to long-term TNFi therapy in patients with PsA treated in
routine clinical practice in the UK.
Methods
Study design and setting
A multicentre, retrospective, observational cohort study
of patients treated with TNFi for PsA was carried out in
11 National Health Service (NHS) hospital Rheumatology
departments in the UK, selected to include specialist
and non-specialist centres with robust mechanisms of
identifying suitable patients with comprehensive medical
records, and providing a wide geographical distribution
to ensure generalizability of results. The study included
eligible patients with PsA with long-term (3 years)
follow-up data available after initiation of the first TNFi.
Data collection took place between 24 April 2015 and
1 December 2015.
Patients
Patients who had been diagnosed with PsA according
to ClASsification criteria for Psoriatic ARthritis (CASPAR)
criteria [22], who were aged 18 years at the start of
TNFi treatment for PsA and first treated with a TNFi be-
tween 1 January 2010 and 31 December 2011 (to focus
on more recent rather than historic clinical practice while
ensuring a minimum of 3 years of follow-up) were eligible
for inclusion in the study. Consecutive (by date) eligible
patients were identified from hospital medical records
by the direct clinical care team and approached to pro-
vide consent to participate in the study, with a maximum
of 20 patients recruited per centre to take into account
the different patient population sizes at each centre
while maintaining a representative geographical distribu-
tion of study patients. Patients gave written informed
consent in accordance with the Declaration of Helsinki
(updated 2008) for retrospective data collection from
medical records according to a protocol approved by
the Research Ethics Committee (REC) East of England –
Norfolk (REC reference number 15/EE/0029).
Sample size
Owing to limited availability of studies reporting longi-
tudinal data for long-term outcomes of TNFi therapy
according to PsARC response and the single-cohort
study design, the target sample size of 150 patients
was selected on a pragmatic basis using an antici-
pated PsARC response rate at 12 weeks after
initiation of first TNFi of 80% (estimated 95% CIs of
73–87%) based on the results of previous studies
[8, 10].
Data collection
Data describing baseline patient demographic and clinical
characteristics, PsARC response components and PsA-
related treatment pathways after initiation of first TNFi
therapy were sourced from medical records, including all
relevant paper notes and electronic databases as appro-
priate in each participating hospital. All data were
recorded in anonymized-coded form on standard data
Key messages
. Long-term treatment of PsA with TNF-a inhibitor may be effective in the majority of patients.
. Successive switching to an alternative TNF-a inhibitor therapy after initial TNF-a inhibitor failure provides progres-
sively less benefit.
. New pathways for therapy in PsA need to be agreed beyond initial TNF-a inhibitor failure.
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collection forms designed for the study. Patient demo-
graphic and clinical characteristics at baseline (data
recorded at the time of initiation or closest before TNFi
initiation) included: age at diagnosis and TNFi initiation,
gender, smoking history, body mass index, co-morbidities
and PsA-related clinical manifestations. The PsARC re-
sponse components recorded at the baseline PsA as-
sessment visit (defined as the Rheumatology outpatient
visit recorded at the time of initiation or closest before
TNFi initiation, during which one or more PsARC compo-
nents were recorded) included: swollen joint count (SJC),
tender joint count (TJC), physician global assessment
(PGA) score and patient global assessment (PtGA) score.
Data on treatment pathways during the observation pe-
riod (from initiation of first TNFi until data collection) in-
cluded: TNFi therapy, duration of treatment for each
different TNFi received, reasons for discontinuing TNFi
therapies, concomitant medication, PsARC response
components, concomitant csDMARD therapy and PsA
therapies after TNFi discontinuation.
Response to TNFi therapy
PsARC response
A PsARC response is achieved if no component is
worse and at least two of the following apply: improve-
ment of 30% in TJC or SJC (at least one required,
based on 68/66 joint count) and/or improvement in PGA
and/or PtGA of at least one point on a five-point Likert
scale [10]. The TJC and SJC were assessed using differ-
ent scores (78/76, 68/66 and 28/28 joint counts) at dif-
ferent centres and by different clinicians. For the
purposes of assessing response to treatment, the 68/66
and 78/76 joint counts were considered to be equiva-
lent, as previously described [23] and pooled for analy-
sis, whereas 28/28 joint counts were analysed
separately (see supplementary methods, available at
Rheumatology Advances in Practice online). The PGA
and PtGA scores were evaluated using different scales
[five-point Likert scale, 10-point visual analog scale
(VAS) or 100-point VAS] at different centres and by dif-
ferent clinicians. Given that each scale is linear, thresh-
olds for improvement or worsening of the PGA and
PtGA scores of at least two points on a 10-point VAS
and 20 points on a 100-point VAS were considered to
be equivalent to least one point on a five-point Likert
scale (only when assessed using the same scale at
baseline and post-TNFi assessment visits). The PsARC
responses after initiation of first TNFi were evaluated
based on the percentage increase or decrease in the
number of SJC and TJC and the number of points in-
crease or decrease in PGA and PtGA, comparing the
scores for the post-TNFi initiation time points with base-
line scores (see supplementary methods, available at
Rheumatology Advances in Practice online).
Treatment persistence
For assessment of the duration of therapy for each
TNFi, any temporary breaks in TNFi therapy were disre-
garded and the duration of therapy for a particular TNFi
was taken as the time from initiation until the date of for-
mal discontinuation or the end of the observation period
(whichever was soonest).
Statistical analyses
All analyses were descriptive in nature and performed
on the available data, with no imputation of missing val-
ues; the denominators for all analyses where data were
missing are presented in the relevant figures, tables or
text. Quantitative variables are presented as the median
[interquartile range (IQR) or range] or arithmetic mean
(S.D.). Nominal variables are presented as the frequency
(percentage) and ordinal variables as the median (IQR).
Results
Baseline patient demographic and clinical
characteristics
One hundred and forty-one patients from 11 hospitals in
the UK treated with first TNFi between January 2010
and December 2011 were included in the study. The
baseline patient demographic and clinical characteristics
at initiation of first TNFi therapy are presented in
Table 1. The mean age of patients at initiation of first
TNFi was 50.3 (S.D.: 12.1) years; 50% of patients were
male, 10% of patients were current smokers, and me-
dian disease duration was 5.7 (IQR: 2.0–11.6) years.
At initiation of first TNFi, 53% of patients had at least
one recorded co-morbidity, and 92% of patients had at
least one PsA-related clinical manifestation (psoriasis,
peripheral arthritis, nail involvement, enthesitis, dactylitis,
axial arthritis). At least one baseline PsARC response
component was recorded before initiation of first TNFi
for 134 (95%) patients, and all four response compo-
nents were recorded for 87 (62%) patients (see supple-
mentary Fig. S1, available at Rheumatology Advances
in Practice online), with a mean time from baseline PsA
assessment to initiation of first TNFi of 6.2 (S.D.: 5.2)
weeks (n¼ 134).
Most patients (76/141) were observed for between
4 and 5 years after initiation of the first TNFi, with a me-
dian observation period of 4.5 (range: 3.4–5.5) years.
The most common first TNFi therapies were adalimumab
(n¼81) and etanercept (n¼ 57), as shown in Fig. 1
(no patients were treated with TNFi biosimilars). Patients
received a median of one (range: one to five) different
TNFi during the observation period. The majority of
patients (67%) received one TNFi, with 11% of patients
receiving three or more TNFi therapies during the obser-
vation period (supplementary Table S1, available at
Rheumatology Advances in Practice online).
Response to TNFi treatment
Response to TNFi treatment was evaluated based on
the available PsARC response components.
TNF-a inhibitor treatment for PsA
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PsARC component responses
Reflecting the real-world design of this study, the
PsARC components were not recorded for all patients
at all time points (see Fig. 2). The PsARC responses
could be determined only at 12 (S.D.: 4) weeks in 47
patients and at 1 year (S.D. 8 weeks) in 27 patients (see
supplementary Fig. S1, available at Rheumatology
Advances in Practice online). The 12-week response
rates for first TNFi were 80 and 79%, respectively, for
SJC and TJC; 79 and 69%, respectively, for PGA and
PtGA; and 79% for PsARC response, as shown in
Fig. 3. Similar response rates were observed at all time
points evaluated during the observation period (see
supplementary Fig. S2, available at Rheumatology
Advances in Practice online).
TNFi treatment persistence
The proportions of patients who remained on the first
TNFi at 1, 2 and 3 years post-initiation were 79, 72 and
65%, respectively, as shown in Fig. 4. At the end of the
observation period, 56% of patients remained on the
first TNFi, 15% of patients were on the second TNFi,
5% of patients were on the third TNFi, 3% of patients
were on at least the fourth different TNFi (see Fig. 4),
and 21% (30/141) of patients had permanently discon-
tinued TNFi therapy [8% (n¼11) after the first, 9%
(n¼13) after the second, 3% (n¼ 4) after the third and
1% (n¼ 2) after the fourth TNFi].
The mean duration of TNFi therapy was 53.6 (S.D.:
6.6) months in patients remaining on the first TNFi
(n¼ 79) and 19.2 (S.D.: 16.6) months in patients who dis-
continued the first TNFi [n¼62; six patients (9.7%) had
discontinued by 3 months]. The most common reasons
for discontinuing the first TNFi were lack of/loss of effi-
cacy (45%) and adverse events (18%), as shown in
Table 2. The mean duration of second TNFi therapy was
31.6 (S.D.: 16.6) months in patients remaining on the sec-
ond TNFi (n¼21) and 11.6 (S.D.: 13.1) months in patients
who discontinued the second TNFi [n¼24; five patients
(21%) had discontinued by 3 months]. The most com-
mon reasons for discontinuation of the second TNFi
were lack of/loss of efficacy (44%) and adverse events
(40%; see Table 2). The mean duration of third TNFi
therapy was 18.1 (S.D.: 15.2) months in patients remain-
ing on the third TNFi (n¼ 7) and 7.8 (S.D.: 7.6) months in
patients who discontinued the third TNFi [n¼9; four
patients (44%) had discontinued by 3 months]. The most
common reason for discontinuation of the third TNFi
was adverse events (56%; see Table 2). The mean dura-
tion of fourth/fifth TNFi therapy was 23.4 (S.D.:
7.6) months in patients remaining on the fourth/fifth TNFi
(n¼ 4) and 8.8 (S.D.: 9.6) months in patients who discon-
tinued the fourth/fifth TNFi [n¼3; one patient (33%) had
discontinued by 3 months]. The most common reason
for discontinuation of the fourth/fifth TNFi was adverse
events (67%; see Table 2).
Co-prescription of csDMARDs
DMARDs were co-prescribed with the first TNFi in
102/137 (74%) patients (77 patients received MTX;
see supplementary Table S2, available at
Rheumatology online). The timing of introduction of
MTX relative to TNFi initiation could be assessed in
74 patients; of these, 64/74 (86%) patients were al-
ready treated with MTX at first TNFi initiation, 5/74
(7%) patients started MTX at the same time as the
first TNFi, and 5/74 (7%) patients started MTX after
initiation of the first TNFi.
TABLE 1 Baseline patient demographic and clinical char-
acteristics at initiation of first TNF-a inhibitor
Characteristic Overall patient
population (n5 141)
Age, mean (S.D.), years 50.3 (12.1)
Males, n (%) 70 (50)
Smokers, n (%)
Current 14 (10)
Former 34 (24)
Never 60 (43)
Unknown 33 (23)
BMI, mean (S.D.), kg/m2 28.7 (5.4) (n¼68)
PsA disease duration, median
(IQR), years
5.7 (2.0–11.6) (n¼138)
Co-morbidities, n (%)
Hypertension 39 (28)
Obesity 30 (21)
Hypercholesterolaemia 24 (17)
Diabetes/high blood glucose 17 (12)
Depression 13 (9)
Coronary heart disease 8 (6)
None 66 (47)
PsA-related clinical manifesta-
tions, n (%)
Psoriasis 118 (84)
Peripheral arthritis 105 (74)
Nail involvement 42 (30)
Enthesitis 27 (19)
Dactylitis 26 (18)
Axial arthritis 17 (12)
None recorded 11 (8)
Swollen joint count, median
(IQR)
(n¼128)
68/66 or 78/76 7.5 (5.0–12.0)
28/28 6.5 (3.8–8.5)
Tender joint count, median
(IQR)
(n¼128)
68/66 or 78/76 17.5 (8.0–27.3)
28/28 15.5 (10.0–22.3)
Physician global assessment
score, median (IQR)
(n¼90)
5-point Likert scale 4 (3–4) (n¼77)
100-point VAS 39.5 (28.5–53.5) (n¼6)
10-point VAS 3 (3.0–3.5) (n¼7)
Patient global assessment
score, median (IQR)
(n¼113)
5-point Likert scale 4 (3–4) (n¼79)
100-point VAS 65.0 (42.5–75.0) (n¼34)
Data are presented as n (%) unless stated otherwise. IQR:
interquartile range; VAS: visual analog scale.
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Treatments for PsA after discontinuation of TNFi
Of the 30 patients (21%) who discontinued TNFi therapy
during the observation period, 7/30 (23%) had received
no further treatments for PsA, 1/30 (3%) patients re-
ceived NSAIDs only, 12/30 (40%) received csDMARDs
only, 1/30 (3%) received a synthetic therapies DMARD
only, 3/30 (10%) received another biologic DMARD only,
and 6/30 (20%) patients received csDMARDs in addition
to one or more other treatments for PsA (see supple-
mentary Table S3, available at Rheumatology online).
Discussion
The baseline demographics and clinical characteristics of
patients with PsA initiated on first- TNFi were broadly sim-
ilar to previously published observational studies in PsA
FIG. 1 First TNF-a inhibitor therapy
Patients were first treated with a TNFi between 1 January 2010 and 31 December 2011. TNFi: TNF inhibitor.
FIG. 2 Scores for individual PsA response criteria components during the study observation period
A
B
(A) Swollen and tender joint counts. (B) Physician and patient global assessments. PGA: physician global assessments;
PsARC: PsA response criteria; PtGA: patient global assessments; SJC: swollen joint counts; TJC: tender joint counts.
TNF-a inhibitor treatment for PsA
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populations [15–20, 24–29]. Although PsARC is the instru-
ment recommended by NICE for assessing response to
TNFi therapy in patients with PsA [3] and was developed
to monitor response to treatment in clinical trials [10, 30],
only one previous longitudinal observational study has
reported PsARC responses to TNFi therapy [26]. Despite
NICE recommendations that TNFi therapy is discontinued
at 12weeks in patients not achieving an adequate re-
sponse using PsARC, sufficient data to assess PsARC
were available in only 33% of patients at 12 weeks and in
only 19% of patients at 1 year, despite nearly 80% of
patients remaining on the first TNFi at 1 year. These find-
ings suggest that NICE guidance is not widely followed
when assessing response to treatment in patients with
PsA in routine UK clinical practice. However, in the small
proportion of patients with PsARC assessments available,
the response rates were 75% at all time points evalu-
ated. Given the extent of missing data, caution is war-
ranted in interpreting these results; however, the similarity
between the proportions of patients achieving improve-
ments in individual PsARC components and the propor-
tion of PsARC responders might suggest that reporting
bias was unlikely. Furthermore, the response rates we ob-
served are consistent with the reported PsARC response
rates of 60% reported in clinical trials for time periods
of 24weeks [8–12, 31]. The response rates are also
consistent with the 56–64% PsARC response rates to dif-
ferent TNFi therapies reported in a prospective observa-
tional open-label study of patients with PsA remaining on
treatment after 5 years [26]. Other previous observational
studies have assessed short-term responses to TNFi
treatment using a variety of clinical measures of disease
activity, including ACR20/50/70, EULAR and DAS28 [15,
16, 18, 25, 26, 28, 32]. Owing to the differences in the re-
sponse components (in particular, use of the 28 joint
count for DAS28, which excludes joints commonly af-
fected in PsA, such as hips, feet and DIP joints) and clas-
sification of overall response for these different measures
[33], it is difficult to compare previous response rates di-
rectly with our study.
Identification of the underlying reasons for the in-
complete reporting of PsARC components was be-
yond the scope of the present study; however,
variability in documenting PsARC component assess-
ments most probably reflects a combination of real-
world factors. These include the complex clinical
manifestations of PsA; the lack of PsA guidelines and
standards and lack of consensus on how and when to
measure disease activity and treatment response; and
a variety of patient-related and service-related factors
(including constraints on outpatient clinic capacity,
impacting on appointment durations and staff
expertise). However, this has important implications
for patients, because poor responses should be docu-
mented clearly in order to support treatment decision-
making.
The EULAR recommendations for the treatment of
PsA highlight the importance of regular (between 1- and
3-monthly) monitoring of disease activity and appropri-
ate adjustment of therapy [6]. EULAR also recommends
the use of composite measures including joint counts
for monitoring disease activity, while acknowledging a
lack of consensus on the best way to monitor disease
activity across different tissues [6]. Joint counts are an
important component of many composite PsA response
measures [33]; consistent with this, we found that joint
FIG. 3 Response to first TNF-a inhibitor at 12 weeks
Bars represent the proportions of patients achieving the following thresholds: joint count 30% improvement; global
assessment improvement of at least one point on five-point Likert scale, 2 points on 10-point VAS, 20 points on
100-point VAS. PGA: physician global assessments; PsARC: PsA response criteria; PtGA: patient global assessments;
SJC: swollen joint counts; TJC: tender joint counts; TNFi: TNF inhibitor; VAS: visual analog scale.
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counts were more frequently recorded than PtGA and
PGA at all time points evaluated. However, it has previ-
ously been shown that joint counts are relatively poor at
predicting changes in treatment [34], reflecting the fact
that peripheral arthritis is only one of the symptoms of
PsA [7, 35]. Consistent with this, most patients included
in this study had documented psoriasis and peripheral
arthritis, and 20% of patients had documented
FIG. 4 TNF-a inhibitor treatment persistence after initiation of first TNF-a inhibitor
A
B
C
D
(A) Percentage of patients remaining on TNFi treatment at 1 year. (B) Percentage of patients remaining on TNFi treat-
ment at 2 years. (C) Percentage of patients remaining on TNFi treatment at 3 years. (D) Percentage of patients
remaining on TNFi treatment at the end of the observation period. TNFi: TNF inhibitor.
TNF-a inhibitor treatment for PsA
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enthesitis and dactylitis. Therefore, although the joint
count responses in our study were broadly consistent
with the available PsARC response rates, caution is war-
ranted in interpretation of these data as a measure of
treatment effectiveness given the poor sensitivity of joint
counts in predicting treatment changes. Furthermore, it
seems likely that the variability in recording PsARC
components, at least in part, reflects the ongoing lack of
consensus regarding the use of composite compared
with unidimensional scoring systems focused on the
specific disease characteristics and health-related qual-
ity of life of individual patients [6, 36]. The limited docu-
mentation of PsARC might suggest poor broad
applicability in routine clinical practice and may call into
question its suitability as the recommended instrument
for assessing response to treatment in NICE PsA guid-
ance. Patient-reported outcome measures such, as the
routine assessment of patient index data 3, might be
more suitable for assessing patients in routine clinical
practice [37, 38].
Most patients received co-prescribed MTX during
treatment with the first TNFi, and the timing of therapy
suggests that MTX was maintained as supportive ther-
apy rather than being prescribed as a rescue therapy or
to improve persistence in most of these patients.
Although co-prescription of MTX with TNFi for the treat-
ment of PsA is reported to be common, it is notable that
evidence from clinical trials and observational studies
suggests that co-prescription of MTX does not improve
the response to TNFi therapy [39].
The majority of observational studies have reported
treatment persistence as a surrogate for clinical effec-
tiveness in assessing longer-term responses to TNFi
treatment; most studies demonstrated that 50% of
patients remained on TNFi therapy a minimum of 2 years
after initiation of first TNFi [14–19, 27, 28, 32, 40], with
only two studies reporting median treatment persistence
of <2 years [20, 29]. One study reported that 86.7% of
patients treated with etanercept who had achieved re-
mission by month 6 (defined as zero joints with synovitis)
remained in remission (discontinuation for any cause
was defined as non-response) at month 66 of follow-up
[40]. This suggests that once remission is achieved with
TNFi therapy it is maintained in the longer term; how-
ever, the study was originally designed to assess
treatment adherence with defined criteria for study with-
drawal [40], suggesting that the results might not be re-
flective of routine clinical practice. Consistent with the
majority of studies, we found that 75% of the patients
remained on TNFi therapy after a median of 4.5 years
follow-up (50% of all patients remained on the first
TNFi). Furthermore, the overall proportion of patients
remaining on treatment was similar to the response
rates for the different PsARC components, which may
support treatment persistence as a marker for treatment
effectiveness in our study. However, it cannot be ex-
cluded that treatment persistence may also reflect a pla-
cebo effect for some patients or a lack of alternative
therapies targeting different inflammatory pathways dur-
ing the observation period of this long-term study. In
this context, it is notable that the average TNFi treat-
ment duration in patients switching TNFi therapy de-
creased and the proportion of patients discontinuing
TNFi therapy within 3 months of initiation increased with
subsequent lines of TNFi, with lack of/loss of efficacy
and intolerance being the most commonly recorded
reasons for discontinuation across successive TNFi ther-
apies. This observation is consistent with previous regis-
try data [15, 20, 29, 41], suggesting many patients are
more resistant and/or intolerant to multiple TNFi after ini-
tial treatment failure. Taken together with the results of
previous studies, our results suggest that long-term
TNFi therapy is well tolerated and may be effective in
50% of patients. However, although switching to a
second TNFi after failure on first therapy owing to either
lack of efficacy or intolerance is recommended by
the British Society of Rheumatology/British Health
Professionals in Rheumatology guidelines [42] and
EULAR guidelines [6], our study adds to the available
evidence suggesting that switching TNFi therapy after
failure on first TNFi may not provide prolonged benefits
for many patients.
At the end of the observation period, approximately
one-fifth of patients had permanently discontinued TNFi
therapy, with the majority of these going on to receive
only conventional DMARD therapy, emphasizing the lack
TABLE 2 Reasons for discontinuing TNF-a inhibitor therapy
Reason for
discontinuationa
TNFi therapy
First TNFi (n5 62) Second TNFi (n525) Third TNFi (n5 9) Fourth/fifth TNFi (n53)
Lack of/loss of efficacy 28 (45) 11 (44) 3 (33) 1 (33)
Adverse events 11 (18) 10 (40) 5 (56) 2 (67)
Injection site reactions 6 (10) 1 (4) – –
Infection/recurrent infection 7 (11) 2 (8) – –
Other 13 (21) 3 (12) 3 (33) –
Not recorded 1 (2) – – –
Data are presented as (%); anot mutually exclusive. TNFi: TNF-a inhibitor.
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of alternative targeted therapies for PsA during the ob-
servation period of the present study. The significant mi-
nority of patients who permanently discontinued TNFi
and the number of patients treated with more than two
lines of TNFi suggest a considerable unmet clinical need
for the treatment of PsA during the observation period
of the present study. However, the recent availability
of newer and emerging therapies targeting different in-
flammatory pathways, including ustekinumab (IL-12/
IL-23 inhibitor), secukinumab (IL-17A inhibitor) and apre-
milast (phosphodiesterase inhibitor), will provide greater
opportunities for more individualized treatment in the fu-
ture [1, 21].
Limitations of the study
Given that informed patient consent was required for
this study, selection bias was possible, which may have
influenced the study end points. All data were sourced
retrospectively from patient medical records, resulting in
varying degrees of missing data for different variables, a
recognized limitation of retrospective epidemiological
studies. The PsARC response was assessed only if the
required variables were recorded within the permitted
time windows for each time point and therefore data
were not available for all patients, which might have bi-
ased response rates. Although most patients had ten-
der/swollen joint counts assessed using the 68/66 or the
78/76 joint counts (considered to be equivalent to the
68/66 joint count for the purposes of the present study),
a small proportion of patients had joint counts assessed
using the 28/28 joint count, which may be unreliable ow-
ing to the likelihood of missing tender and swollen joints
at baseline and/or follow-up, particularly given the signif-
icant involvement of feet in PsA [35]. Furthermore, we
cannot exclude the possibility that the documentation of
PsARC response components may have differed in
patients responding and not responding to TNFi therapy.
Temporary breaks in TNFi therapy were disregarded
when calculating the duration of treatment for each
TNFi, and the number and duration of temporary breaks
is unknown. Although the impact is likely to be small,
this will have resulted in an overestimation of overall
TNFi treatment persistence. Treatment persistence
might not reflect a favourable effect of TNFi on PsA dis-
ease severity, because patients might have remained on
treatment owing to the lack of alternative non-TNFi bio-
logic therapies during the observation period, and we
were unable to correlate treatment persistence with
PsARC responses owing to the limited data available.
The patients in our cohort commenced first TNFi be-
tween 2010 and 2011 to ensure a minimum of 3 years of
follow-up; as a result, our data may not be reflective of
current clinical practice.
Conclusion
Long-term TNFi therapy is well tolerated and may be ef-
fective in 50% of patients based on TNFi persistence.
However, changing to an alternative TNFi therapy may
provide less benefit and may result in more adverse
effects for some patients after failure of the first and
subsequent TNFi. The recent availability of newer and
emerging therapies targeting different inflammatory
pathways will enable more individualized treatment for
patients with PsA in the future. Our data also suggest
that NICE recommendations regarding the assessment
of response to TNFi therapy based on PsARC response
are not widely followed, which might reflect poor broad
applicability in the routine clinical practice setting. Given
the changing landscape of PsA management in the UK,
a future study evaluating the impact of these newer tar-
geted therapies on outcomes in patients with PsA not
adequately controlled by conventional DMARDs and for
whom TNFi therapy has not been successful is
warranted.
Acknowledgements
The authors wish to thank pH Associates, a healthcare
consultancy company specializing in real-world evalua-
tion, who supported Novartis and the authors in the
conduct of this research, analysis of the results and re-
view and approval of this manuscript. The authors grate-
fully acknowledge A. M. Carter from pH Associates for
medical writing assistance in the preparation and revi-
sion of this manuscript.
Funding: This work was supported by Novartis
Pharmaceuticals UK Ltd who were involved in the study
design, implementation and interpretation the data
and the drafting, revision and final approval of this
manuscript.
Disclosure statement: G.C. has received honoraria for
lecturing and delivering educational sessions from:
Novartis, Pfizer, Amgen, Celgene and Janssen. I.B.M.
has received grants and personal fees from Abbvie,
BMS, Novartis, Celgene, Janssen, Pfizer and UCB. N.B.
has received grants from Novartis, personal fees from
Novartis, grants from Eli Lilly and grants from Abbvie.
H.M.-O. has received grants from Janssen and Pfizer
and honoraria from Abbvie, Celgene, Janssen, Pfizer,
Novartis and UCB. J.P. has received personal fees from
Abbvie. B.K. has received grant/research support from
AbbVie, Eli Lilly & Co., Novartis, Roche and UCB; is a
consultant for Eli Lilly & Co., Novartis and Sandoz; and
a speaker’s bureau member for Novartis and Pfizer.
H.C. was an employee of Novartis at the time this study
was carried out. A.B.-B. is an employee of pH
Associates. N.M. has received grants from Novartis,
grants and personal fees from Celgene, personal fees
from Eli Lilly, personal fees from Abbvie and grants from
UCB. The other authors have declared no conflicts of
interest.
Supplementary data
Supplementary data are available at Rheumatology
Advances in Practice online.
TNF-a inhibitor treatment for PsA
https://academic.oup.com/rheumap 9
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
ap/article-abstract/2/2/rky042/5133614 by U
niversity of Leeds Library user on 18 April 2019
References
1 Huynh D, Kavanaugh A. Psoriatic arthritis: current
therapy and future approaches. Rheumatology 2015;54:
20–8.
2 Ogdie A, Weiss P. The epidemiology psoriatic arthritis.
Rheum Dis Clin North Am 2015;41:545–68.
3 NICE. Etanercept, Infliximab and Adalimumab for the
Treatment of Psoriatic Arthritis: Guidance and Guidelines
(TA199). 2010. http://www.nice.org.uk/guidance/ta199
(1 February 2016, date last accessed).
4 Yeon Paek S, Han L, Weiland M et al. Emerging
biomarkers in psoriatic arthritis. IUBMB Life 2015;67:
923–7.
5 Olivieri I, D’Angelo S, Palazzi C, Padula A. Advances in
the management of psoriatic arthritis. Nat Rev
Rheumatol 2014;10:531–42.
6 Gossec L, Smolen JS, Ramiro S et al. European League
Against Rheumatism (EULAR) recommendations for the
management of psoriatic arthritis with pharmacological
therapies: 2015 update. Ann Rheum Dis 2016;75:
499–510.
7 Coates LC, Kavanaugh A, Mease PJ et al. Group for
Research and Assessment of Psoriasis and Psoriatic
Arthritis 2015 treatment recommendations for psoriatic
arthritis. Arthritis Rheumatol 2016;68:1060–71.
8 Antoni C, Krueger GG, de Vlam K et al. Infliximab
improves signs and symptoms of psoriatic arthritis:
results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:
1150–7.
9 Kavanaugh A, McInnes I, Mease P et al. Golimumab, a
new human tumor necrosis factor a antibody,
administered every four weeks as a subcutaneous
injection in psoriatic arthritis: twenty-four-week efficacy
and safety results of a randomized, placebo-controlled
study. Arthritis Rheum 2009;60:976–86.
10 Mease PJ, Goffe BS, Metz J et al. Etanercept in the
treatment of psoriatic arthritis and psoriasis: a
randomised trial. Lancet 2000;356:385–90.
11 Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab
for the treatment of patients with moderately to severely
active psoriatic arthritis: results of a double-blind, ran-
domized, placebo-controlled trial. Arthritis Rheum 2005;
52:3279–89.
12 Mease PJ, Fleischmann R, Deodhar AA et al. Effect of
certolizumab pegol on signs and symptoms in patients
with psoriatic arthritis: 24-week results of a Phase 3
double-blind randomised placebo-controlled study
(RAPID-PsA). Ann Rheum Dis 2014;73:48–55.
13 NICE. Golimumab for the Treatment of Psoriatic Arthritis:
Guidance and Guidelines (TA220). 2011. http://www.
nice.org.uk/guidance/ta220 (1 February 2016, date last
accessed).
14 Saad AA, Ashcroft DM, Watson KD et al. Persistence
with anti-tumour necrosis factor therapies in patients
with psoriatic arthritis: observational study from the
British Society of Rheumatology Biologics Register.
Arthritis Res Ther 2009;11:R52.
15 Glintborg B, Østergaard M, Krogh NS et al. Clinical
response, drug survival, and predictors thereof among
548 patients with psoriatic arthritis who switched tumor
necrosis factor a inhibitor therapy: results from the
Danish Nationwide DANBIO Registry. Arthritis Rheum
2013;65:1213–23.
16 Kristensen LE, Gu¨lfe A, Saxne T, Geborek P. Efficacy
and tolerability of anti-tumour necrosis factor therapy in
psoriatic arthritis patients: results from the South
Swedish Arthritis Treatment Group register. Ann Rheum
Dis 2007;67:364–9.
17 Simard JF, Arkema EV, Sundstro¨m A et al. Ten years
with biologics: to whom do data on effectiveness and
safety apply? Rheumatology 2011;50:204–13.
18 Fagerli KM, Lie E, van der Heijde D et al. The role of
methotrexate co-medication in TNF-inhibitor treatment in
patients with psoriatic arthritis: results from 440 patients
included in the NOR-DMARD study. Ann Rheum Dis
2014;73:132–7.
19 Carmona L, Go´mez-Reino JJ. Survival of TNF
antagonists in spondylarthritis is better than in
rheumatoid arthritis. Data from the Spanish registry
BIOBADASER. Arthritis Res Ther 2006;8:R72.
20 Harrold LR, Stolshek BS, Rebello S et al. Impact of prior
biologic use on persistence of treatment in patients with
psoriatic arthritis enrolled in the US Corrona registry. Clin
Rheumatol 2017;36:895–901.
21 Ungprasert P, Thongprayoon C, Davis JM. Indirect
comparisons of the efficacy of subsequent biological
agents in patients with psoriatic arthritis with an
inadequate response to tumor necrosis factor inhibitors:
a meta-analysis. Clin Rheumatol 2016;35:1795–803.
22 Taylor W, Gladman D, Helliwell P et al. Classification
criteria for psoriatic arthritis: development of new criteria
from a large international study. Arthritis Rheum 2006;54:
2665–73.
23 Day SH, Butt S, Deighton C, Gadsby K. The
consequence of using different methods of joint
assessment on the eligibility for access to anti-TNF in
psoriatic arthritis. Rheumatology 2010:i17. https://rheu
matology.oxfordjournals.org/content/49/suppl_1/i14.full
(11 March 2016, date last accessed).
24 Jani M, Macphie E, Rao C et al. Effectiveness of
switching between biologics in psoriatic arthritis- results
of a large regional survey. Clin Med 2014;14:95–6.
25 Saad AA, Ashcroft DM, Watson KD et al. Efficacy and
safety of anti-TNF therapies in psoriatic arthritis: an ob-
servational study from the British Society for
Rheumatology Biologics Register. Rheumatology 2010;
49:697–705.
26 Saougou I, Markatseli TE, Papagoras C et al.
Sustained clinical response in psoriatic arthritis
patients treated with anti-TNF agents: a 5-year open-
label observational cohort study. Semin Arthritis
Rheum 2011;40:398–406.
27 Mease PJ, Collier DH, Saunders KC et al. Comparative
effectiveness of biologic monotherapy versus
combination therapy for patients with psoriatic arthritis:
results from the Corrona registry. RMD Open 2015;1:
e000181.
28 Iannone F, Lopriore S, Bucci R et al. Two-year survival
rates of anti-TNF-a therapy in psoriatic arthritis (PsA)
Gavin Clunie et al.
10 https://academic.oup.com/rheumap
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
ap/article-abstract/2/2/rky042/5133614 by U
niversity of Leeds Library user on 18 April 2019
patients with either polyarticular or oligoarticular PsA.
Scand J Rheumatol 2015;44:192–9.
29 Svedbom A, Dale´n J, Black CM, Kachroo S. Persistence
and costs with subcutaneous TNF-alpha inhibitors in
immune-mediated rheumatic disease stratified by treat-
ment line. Patient Prefer Adherence 2017;11:95–106.
30 Clegg DO, Reda DJ, Mejias E et al. Comparison of
sulfasalazine and placebo in the treatment of psoriatic
arthritis. A Department of Veterans Affairs Cooperative
Study. Arthritis Rheum 1996;39:2013–20.
31 Sterry W, Ortonne J-P, Kirkham B et al. Comparison of
two etanercept regimens for treatment of psoriasis and
psoriatic arthritis: PRESTA randomised double blind
multicentre trial. BMJ 2010;340:c147.
32 Glintborg B, Østergaard M, Dreyer L et al. Treatment
response, drug survival, and predictors thereof in 764
patients with psoriatic arthritis treated with anti-tumor
necrosis factor a therapy: results from the nationwide
Danish DANBIO registry. Arthritis Rheum 2011;63:
382–90.
33 Mease PJ. Measures of psoriatic arthritis: Tender and
Swollen Joint Assessment, Psoriasis Area and Severity
Index (PASI), Nail Psoriasis Severity Index (NAPSI),
Modified Nail Psoriasis Severity Index (mNAPSI),
Mander/Newcastle Enthesitis Index (MEI), Leeds
Enthesitis Index (LEI), Spondyloarthritis Research
Consortium of Canada (SPARCC), Maastricht Ankylosing
Spondylitis Enthesis Score (MASES), Leeds Dactylitis
Index (LDI), Patient Global for Psoriatic Arthritis,
Dermatology Life Quality Index (DLQI), Psoriatic Arthritis
Quality of Life (PsAQOL), Functional Assessment of
Chronic Illness Therapy–Fatigue (FACIT-F), Psoriatic
Arthritis Response Criteria (PsARC), Psoriatic Arthritis
Joint Activity Index (PsAJAI), Disease Activity in Psoriatic
Arthritis (DAPSA), and Composite Psoriatic Disease
Activity Index (CPDAI). Arthritis Care Res 2011;63:
S64–85.
34 Coates LC, FitzGerald O, Gladman DD et al. Reduced
joint counts misclassify patients with oligoarticular
psoriatic arthritis and miss significant numbers of
patients with active disease. Arthritis Rheum 2013;65:
1504–9.
35 Ko¨hm M, Burkhardt H, Behrens F. Anti-TNFa-therapy as
an evidence-based treatment option for different clinical
manifestations of psoriatic arthritis. Clin Exp Rheumatol
2015;33:S109–14.
36 Smolen JS, Scho¨ls M, Braun J et al. Treating axial
spondyloarthritis and peripheral spondyloarthritis,
especially psoriatic arthritis, to target: 2017 update of
recommendations by an international task force. Ann
Rheum Dis 2018;77:3–17.
37 Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3
(Routine Assessment of Patient Index Data 3), a
rheumatoid arthritis index without formal joint counts for
routine care: proposed severity categories compared to
disease activity score and clinical disease activity index
categories. J. Rheumatol 2008;35:2136–47.
38 Michelsen B, Fiane R, Diamantopoulos AP et al. A
comparison of disease burden in rheumatoid arthritis,
psoriatic arthritis and axial spondyloarthritis. PLoS One
2015:10:e0123582.
39 Behrens F, Ca~nete JD, Olivieri I et al. Tumour necrosis
factor inhibitor monotherapy vs combination with MTX in
the treatment of PsA: a systematic review of the
literature. Rheumatology 2015;54:915–26.
40 de Vlam K, Bruhwyler J, Boone C, and the PROVE Study
Group. Maintenance of remission and monotherapy status
over 66 months in patients with psoriatic arthritis receiving
etanercept. Clin Exp Rheumatol 2016;34:1094–7.
41 Fagerli KM, Lie E, van der Heijde D, et al. Switching
between TNF inhibitors in psoriatic arthritis: data from
the NOR-DMARD study. Ann Rheum Dis 2013;72:
1840–4.
42 Coates LC, Tillett W, Chandler D et al. The 2012 BSR
and BHPR guideline for the treatment of psoriatic
arthritis with biologics. Rheumatology 2013;52:
1754–7.
TNF-a inhibitor treatment for PsA
https://academic.oup.com/rheumap 11
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
ap/article-abstract/2/2/rky042/5133614 by U
niversity of Leeds Library user on 18 April 2019
